Adjuvant Therapies: Time to Fold or Double Down?
Benjamin T Ristau, MD, and Robert G. Uzzo, MD, FACS, examine why adjuvant therapies have been so ineffective.
Benjamin T Ristau, MD, and Robert G. Uzzo, MD, FACS, examine why adjuvant therapies have been so ineffective.
Prostatic arterial embolization significantly reduced volumes of median lobes, central zones, peripheral zones, and whole prostate glands.
True prevalence of hypospadias and related trends are difficult to estimate.
Statin users had 30% increased odds of acute kidney injury and 36% increased odds of chronic kidney disease compared with non-users.
SWL treatment success rate was 70.4% and 53.1% for stones less than 15 mm and 15 mm or larger, respectively.
Use of oral megestrol acetate (MA) is associate with significant adverse effects.
Enzalutamide reduced the risk of disease progression by 56% in mCRPC patients.
Results of some urine and blood tests are unlikely to affect diagnosis or management of acute kidney injury.
A combination of exercise and a flavonoid-rich diet can reduce the risk of erectile dysfunction by 21%.
Older age and a second episode of urinary tract infection identified as risk factors.